NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
21/02/2026
Voltar para busca
Dado oficial do USPTO
XBRANE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
17/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10, 42
Data de depósito
12/11/2018
Data de registro
10/03/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/02/2026
Última transação
17/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
09
Localização do titular
SOLNA, SE
Examinador
GARDNER, DAWNA BERYL
Localização atual
Historical data usage
Descrição da marca
The mark consists of the stylized light blue and dark blue wording "XBRANE".
Titulares e representantes
Titulares
Xbrane Biopharma AB
Xbrane Biopharma AB
Representantes
Andy I. Corea Harris Beach Murtha Cullina PLLC
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and medical preparations all for treating cancerendometriosismyomaeye diseasesage related macular degenerationskin diseasesprecocious pubertyvascular diseasescardiovascular diseases and disordersoncological diseases and disordersimmune diseases and disordersautoimmune diseasesangiogenesis diseases and disordersgenetic conditionsinfectious diseasesocular diseases and disordersinflammatory diseases and disordersrheumatoid arthritispsoriatic arthritisankylosing spondylitispsoriasisCrohn's diseaseulcerative colitisdiabetesdiabetic macular edemadiabetic related retinopathymultiple sclerosisarthritisosteoporosisbone metastasis; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating cancerendometriosismyomaeye diseasesage related macular degenerationskin diseasesprecocious pubertyvascular diseasescardiovascular diseases and disordersoncological diseases and disordersimmune diseases and disordersautoimmune diseasesangiogenesis diseases and disordersgenetic conditions and infectious diseases; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating ocular diseases and disordersinflammatory diseases and disordersrheumatoid arthritispsoriatic arthritisankylosing spondylitispsoriasisCrohn's diseaseulcerative colitisdiabetesdiabetic macular edemadiabetic related retinopathymultiple sclerosisarthritisosteoporosisbone metastasis; chemotherapeutics; hormones for medical purposes; pharmaceutical agents for treating metabolic disorders; amino acids for medical purposes; pharmaceutical agents for treating immunity disorders; pharmaceutical agents for treating physically caused lesions; antiviral preparations; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosistreatment and prevention of cancerendometriosismyomaeye diseasesage related macular degenerationskin diseasesprecocious pubertyvascular diseasescardiovascular diseases and disordersoncological diseases and disordersimmune diseases and disordersautoimmune diseasesangiogenesis diseases and disordersgenetic conditionsinfectious diseases; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosistreatment and prevention of ocular diseases and disordersinflammatory diseases and disordersrheumatoid arthritispsoriatic arthritisankylosing spondylitispsoriasisCrohn's diseaseulcerative colitisdiabetesdiabetic macular edemadiabetic related retinopathymultiple sclerosisarthritisosteoporosis and bone metastasis
Classe 10
Surgical apparatus and instruments; injection device for pharmaceuticals; injection syringes; injection needles; medical apparatusautomatic infusion and injection devices for administering drugs to humans
Classe 42
Scientific and medical research and development; pharmaceutical research and development services; research and development services in the fields of biological similar pharmaceuticalsgeneric drugsbiotechnologydiagnostics and pharmaceuticals; consultancy services relating to the discovery and evaluation of drugs and chemical compounds having diagnostic properties and therapeutic properties; technical support servicestroubleshooting in the nature of diagnosing problems with medical equipment; diagnostic services in the field of troubleshooting biotechnology and pharmaceutical equipment for scientific research purposes; analyzing biotechnology and pharmaceutical equipment for scientific research purposes; development of new technology for others in the field of biotechnology; medicalpharmaceutical and biotechnological laboratory research services; informationconsultancy and advisory services relating to scientific and medical research and developmentbiotechnological and pharmaceutical research and development and medical equipment research and development
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
21/02/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/02/2026
ES71
TEAS SECTION 71 RECEIVED
03/10/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/03/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/07/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/07/2020
FIMP
FINAL DISPOSITION PROCESSED
11/07/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/06/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
10/03/2020
GPNX
NOTIFICATION PROCESSED BY IB
03/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
24/12/2019
PUBO
PUBLISHED FOR OPPOSITION
24/12/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/12/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/12/2019
ALIE
ASSIGNED TO LIE
19/11/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/11/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/11/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/11/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/11/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
09/07/2019
GNFR
FINAL REFUSAL E-MAILED
09/07/2019
CNFR
FINAL REFUSAL WRITTEN
09/07/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/06/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/06/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/06/2019
RFNT
REFUSAL PROCESSED BY IB
06/04/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/03/2019
RFRR
REFUSAL PROCESSED BY MPU
20/03/2019
MAFR
APPLICATION FILING RECEIPT MAILED
09/03/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/03/2019
CNRT
NON-FINAL ACTION WRITTEN
07/03/2019
DOCK
ASSIGNED TO EXAMINER
05/03/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/03/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
28/02/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace XBRANE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.